- Evonik opens new facility for drying EUDRAGIT polymers at its Darmstadt site to enhance oral drug delivery solutions.
- The expansion addresses rising pharmaceutical demand while reducing CO2 emissions and improving supply chain efficiency.
Evonik has inaugurated a new excipient manufacturing facility at its Darmstadt site, aimed at drying aqueous dispersions of its well-known EUDRAGIT polymers. The investment, a double-digit million-euro project, enhances production capacity to meet growing demand from pharmaceutical companies for oral drug delivery solutions.
The facility will help secure supply chains and shorten delivery times for EUDRAGIT polymers, which are used in various drug delivery applications. The plant operates using green electricity and steam from local waste incineration, saving over 1,000 CO2 equivalents annually. The Darmstadt site has long been a centre for oral drug delivery innovation and is now Evonik’s European headquarters for healthcare and a global hub for drug delivery system solutions.
“Our new facility enables our customers to develop oral drugs more efficiently and innovatively, improving the lives of more patients worldwide,” said Harald Schwager, Deputy CEO of Evonik.
Built according to IPEC-GMP pharmaceutical guidelines, the new plant is directly linked to the production unit for aqueous EUDRAGIT dispersions. This integration reduces transportation needs, further enhancing sustainability. EUDRAGIT polymers are widely used in the pharmaceutical industry, offering flexibility in matching various drug release profiles such as immediate, delayed, and sustained release.
Stay ahead of trends and best practices
